JP2023531269A - キナゾリン化合物、その製造方法および用途 - Google Patents
キナゾリン化合物、その製造方法および用途 Download PDFInfo
- Publication number
- JP2023531269A JP2023531269A JP2022580317A JP2022580317A JP2023531269A JP 2023531269 A JP2023531269 A JP 2023531269A JP 2022580317 A JP2022580317 A JP 2022580317A JP 2022580317 A JP2022580317 A JP 2022580317A JP 2023531269 A JP2023531269 A JP 2023531269A
- Authority
- JP
- Japan
- Prior art keywords
- group
- ring
- acceptable salt
- compound according
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020099104 | 2020-06-30 | ||
| CNPCT/CN2020/099104 | 2020-06-30 | ||
| CN2021075828 | 2021-02-07 | ||
| CNPCT/CN2021/075828 | 2021-02-07 | ||
| PCT/CN2021/103372 WO2022002102A1 (en) | 2020-06-30 | 2021-06-30 | Quinazoline compounds, preparation methods and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531269A true JP2023531269A (ja) | 2023-07-21 |
| JPWO2022002102A5 JPWO2022002102A5 (https=) | 2024-06-24 |
| JP2023531269A5 JP2023531269A5 (https=) | 2024-06-24 |
Family
ID=79317503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580317A Pending JP2023531269A (ja) | 2020-06-30 | 2021-06-30 | キナゾリン化合物、その製造方法および用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230242544A1 (https=) |
| EP (1) | EP4175947A4 (https=) |
| JP (1) | JP2023531269A (https=) |
| CN (1) | CN115836055A (https=) |
| WO (1) | WO2022002102A1 (https=) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023537999A (ja) * | 2020-08-12 | 2023-09-06 | ジェネンテック， インコーポレイテッド | キナゾリン化合物の合成 |
| JP2024508755A (ja) * | 2021-02-16 | 2024-02-28 | セラス， インコーポレイテッド | Ｋｒａｓを阻害するための組成物及び方法 |
| JP2024510606A (ja) * | 2021-03-12 | 2024-03-08 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| JP2024517693A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | ２－アミノベンゾチアゾール化合物及びその使用方法 |
| JP2024517695A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| JP2024522187A (ja) * | 2021-06-09 | 2024-06-11 | イーライ リリー アンド カンパニー | Ｋｒａｓ ｇ１２ｄ阻害剤としての置換縮合アジン |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| CN113164418A (zh) | 2018-12-05 | 2021-07-23 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2022056307A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| US20240059710A1 (en) * | 2020-11-20 | 2024-02-22 | Jacobio Pharmaceuticals Co., Ltd. | KRAS G12D Inhibitors |
| WO2022132200A1 (en) | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| BR112023015976A2 (pt) * | 2021-02-09 | 2023-12-12 | Medshine Discovery Inc | Compostos de anel aromático de pirimidina |
| CN115260214A (zh) * | 2021-04-29 | 2022-11-01 | 药雅科技(上海)有限公司 | 稠环类krasg12d突变蛋白抑制剂的制备及其应用 |
| CN115160309B (zh) * | 2021-04-07 | 2024-04-09 | 药雅科技(上海)有限公司 | Krasg12c突变蛋白杂环类抑制剂的制备及其应用 |
| CN115141215B (zh) * | 2021-03-30 | 2023-09-15 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| WO2022214102A1 (zh) * | 2021-04-09 | 2022-10-13 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的杂环化合物 |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| WO2022221739A1 (en) * | 2021-04-16 | 2022-10-20 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12d mutant |
| CN117222650A (zh) * | 2021-04-30 | 2023-12-12 | 劲方医药科技(上海)有限公司 | 吡啶或嘧啶并环类化合物，其制法与医药上的用途 |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| CN115385938A (zh) * | 2021-05-25 | 2022-11-25 | 江苏恒瑞医药股份有限公司 | 苯并嘧啶类化合物、其制备方法及其在医药上的应用 |
| JP2024520791A (ja) * | 2021-06-10 | 2024-05-24 | レデックス・ファーマ・パブリック・リミテッド・カンパニー | 化合物 |
| WO2022262686A1 (en) * | 2021-06-13 | 2022-12-22 | Jingrui Biopharma Co., Ltd. | Kras g12d inhibitors |
| US20240293558A1 (en) | 2021-06-16 | 2024-09-05 | Erasca, Inc. | Kras inhibitor conjugates |
| WO2023278600A1 (en) * | 2021-06-30 | 2023-01-05 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of kras g12d mutant |
| EP4373822A2 (en) | 2021-07-23 | 2024-05-29 | Theras Inc. | Compositions and methods for inhibition of ras |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| US20240409558A1 (en) * | 2021-09-13 | 2024-12-12 | Biomea Fusion, Inc. | Irreversible inhibitors of kras |
| WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| EP4417606A4 (en) * | 2021-10-15 | 2025-10-22 | Sunshine Lake Pharma Co Ltd | NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF |
| WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| WO2023103523A1 (zh) * | 2021-12-09 | 2023-06-15 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| MX2024008849A (es) * | 2022-01-21 | 2024-07-25 | Usynova Pharmaceuticals Ltd | Compuestos de benzopirimidina y uso de estos. |
| IL314486A (en) * | 2022-02-03 | 2024-09-01 | Mirati Therapeutics Inc | Quinazoline compounds inhibit PAN-KRAS |
| AU2023218370B2 (en) | 2022-02-09 | 2024-11-28 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2023151621A1 (zh) * | 2022-02-11 | 2023-08-17 | 泰励生物科技（上海）有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| EP4479398A1 (en) * | 2022-02-16 | 2024-12-25 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| CN114573438A (zh) * | 2022-03-31 | 2022-06-03 | 上海应用技术大学 | 一种单氟氯/溴代丙酮类化合物及其制备方法 |
| CN116891488B (zh) * | 2022-04-11 | 2025-12-12 | 成都海博为药业有限公司 | 稠环化合物、包含其的药物组合物及应用 |
| CN119585287A (zh) | 2022-05-06 | 2025-03-07 | Paq医疗公司 | Kras g12d蛋白水解靶向嵌合体 |
| IL317601A (en) | 2022-05-25 | 2025-02-01 | Quanta Therapeutics Inc | Pyrimidine-based modulators and their uses |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202400600A (zh) * | 2022-06-16 | 2024-01-01 | 美商昂勝醫療科技股份有限公司 | 喹唑啉衍生物、其組成物及方法 |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| TW202409002A (zh) | 2022-07-21 | 2024-03-01 | 日商安斯泰來製藥股份有限公司 | 作用於g12d突變kras蛋白之雜環化合物 |
| JP2025525938A (ja) * | 2022-08-05 | 2025-08-07 | セラス， インコーポレイテッド | Ｋｒａｓの阻害のための組成物及び方法 |
| WO2024030647A1 (en) * | 2022-08-05 | 2024-02-08 | Theras, Inc. | Compositions and methods for inhibition of ras |
| TW202412790A (zh) | 2022-08-09 | 2024-04-01 | 日商安斯泰來製藥股份有限公司 | 用於抑制及/或誘導分解kras蛋白之雜環化合物 |
| EP4568952A1 (en) | 2022-08-11 | 2025-06-18 | Bristol-Myers Squibb Company | Kras inhibitors |
| JP7733274B1 (ja) | 2022-08-12 | 2025-09-02 | アステラス製薬株式会社 | Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ |
| AR130192A1 (es) * | 2022-08-12 | 2024-11-13 | Astellas Pharma Inc | Combinaciones antineoplásicas que comprenden quimioterapia |
| CN119855815A (zh) * | 2022-09-21 | 2025-04-18 | 甘李药业股份有限公司 | 一种kras突变蛋白抑制剂、及其制备方法和应用 |
| AU2023349002A1 (en) * | 2022-09-30 | 2025-05-15 | Trasveda Ltd. | Compounds with anti-kras mutant tumor activity |
| CN117886833A (zh) * | 2022-10-13 | 2024-04-16 | 广东东阳光药业股份有限公司 | 一种嘧啶并吡啶化合物、其药物组合物及其用途 |
| CN117263959A (zh) * | 2022-10-24 | 2023-12-22 | 药雅科技(上海)有限公司 | 芳香类kras突变蛋白抑制剂的制备及其应用 |
| JP2026504244A (ja) | 2022-11-09 | 2026-02-04 | レヴォリューション・メディスンズ，インコーポレイテッド | 化合物、複合体、ならびにそれらの調製方法及びそれらの使用方法 |
| CN116554208A (zh) * | 2022-12-02 | 2023-08-08 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| WO2024158242A1 (ko) * | 2023-01-25 | 2024-08-02 | 주식회사 엔바이오스 | Kras g12d 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물 |
| WO2024192424A1 (en) | 2023-03-15 | 2024-09-19 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| AR133027A1 (es) | 2023-06-22 | 2025-08-20 | Astellas Pharma Inc | Composición farmacéutica que comprende un compuesto de quinazolina |
| WO2025002302A1 (zh) * | 2023-06-28 | 2025-01-02 | 广东东阳光药业股份有限公司 | 嘧啶并吡啶化合物、其药物组合物及其用途 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025051242A1 (zh) * | 2023-09-08 | 2025-03-13 | 泰励生物科技（上海）有限公司 | Ras抑制剂 |
| US12599672B2 (en) | 2023-10-03 | 2026-04-14 | PAQ Therapeutics Inc. | KRAS proteolysis targeting chimeras |
| TW202523324A (zh) * | 2023-10-08 | 2025-06-16 | 大陸商成都海博為藥業有限公司 | 一種稠環化合物及應用 |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024357850A1 (en) | 2023-10-09 | 2026-04-23 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025077770A1 (zh) * | 2023-10-10 | 2025-04-17 | 成都海博为药业有限公司 | 一种稠环化合物及在kras抑制剂方面的应用 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025085580A1 (en) * | 2023-10-17 | 2025-04-24 | Windermere Therapeutics, Inc. | Kras(g12d) inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2021107160A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014331794C1 (en) * | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| US10011600B2 (en) * | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| KR20180081596A (ko) * | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| AU2018271990A1 (en) * | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| US20220363681A1 (en) * | 2019-08-16 | 2022-11-17 | Genfleet Therapeutics (Shanghai) Inc. | Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof |
| US20230081426A1 (en) * | 2020-09-18 | 2023-03-16 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| WO2022098625A1 (en) * | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US20240059710A1 (en) * | 2020-11-20 | 2024-02-22 | Jacobio Pharmaceuticals Co., Ltd. | KRAS G12D Inhibitors |
-
2021
- 2021-06-30 WO PCT/CN2021/103372 patent/WO2022002102A1/en not_active Ceased
- 2021-06-30 EP EP21833587.5A patent/EP4175947A4/en active Pending
- 2021-06-30 US US18/011,138 patent/US20230242544A1/en active Pending
- 2021-06-30 JP JP2022580317A patent/JP2023531269A/ja active Pending
- 2021-06-30 CN CN202180046601.4A patent/CN115836055A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2021107160A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023537999A (ja) * | 2020-08-12 | 2023-09-06 | ジェネンテック， インコーポレイテッド | キナゾリン化合物の合成 |
| JP7585462B2 (ja) | 2020-08-12 | 2024-11-18 | ジェネンテック， インコーポレイテッド | キナゾリン化合物の合成 |
| US12172982B2 (en) | 2020-08-12 | 2024-12-24 | Genentech, Inc. | Synthesis of quinazoline compounds |
| JP2024508755A (ja) * | 2021-02-16 | 2024-02-28 | セラス， インコーポレイテッド | Ｋｒａｓを阻害するための組成物及び方法 |
| JP2024510606A (ja) * | 2021-03-12 | 2024-03-08 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| JP2024517693A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | ２－アミノベンゾチアゾール化合物及びその使用方法 |
| JP2024517695A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| JP2024522187A (ja) * | 2021-06-09 | 2024-06-11 | イーライ リリー アンド カンパニー | Ｋｒａｓ ｇ１２ｄ阻害剤としての置換縮合アジン |
| JP7668908B2 (ja) | 2021-06-09 | 2025-04-25 | イーライ リリー アンド カンパニー | Ｋｒａｓ ｇ１２ｄ阻害剤としての置換縮合アジン |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230242544A1 (en) | 2023-08-03 |
| EP4175947A4 (en) | 2024-07-03 |
| CN115836055A (zh) | 2023-03-21 |
| WO2022002102A1 (en) | 2022-01-06 |
| EP4175947A1 (en) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531269A (ja) | キナゾリン化合物、その製造方法および用途 | |
| JP7837952B2 (ja) | ヘテロアリール基化合物、その製造方法および使用 | |
| CN113748114B (zh) | 一种喹唑啉化合物及其在医药上的应用 | |
| TW202144339A (zh) | 稠環化合物、其製備方法、藥物組合物及其應用 | |
| KR102002277B1 (ko) | Ｊａｋ 저해제를 제조하기 위한 방법 및 중간체 | |
| KR102677015B1 (ko) | Bet 억제제로서의 헤테로시클릭 화합물 | |
| JP2022523786A (ja) | ピラジン誘導体およびｓｈｐ２の阻害の際のその適用 | |
| RU2666349C2 (ru) | Новое конденсированное пиримидиновое соединение или его соль | |
| CN117586280A (zh) | Kras g12d抑制剂及其在医药上的应用 | |
| KR101797046B1 (ko) | 중수소화된 페닐 아미노 피리미딘 화합물 및 이 화합물을 함유하는 약물 조성물 | |
| CN117624190A (zh) | Kras g12d抑制剂及其在医药上的应用 | |
| CN117924327A (zh) | 具有大环结构的Kras抑制剂化合物 | |
| AU2016292450B2 (en) | Aniline pyrimidine derivatives and uses thereof | |
| AU2021200974B2 (en) | A solid state form of pladienolide pyridine compounds and methods of use | |
| WO2025053850A1 (en) | Covalent kras-binding compounds for medical treatment | |
| CA2990083A1 (en) | Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| KR20110007208A (ko) | 페닐 또는 피리디닐 치환된 인다졸 유도체 | |
| JP2018513219A (ja) | 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用 | |
| CN118994158A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| JP2024532845A (ja) | ピリダジノンまたはピリジノン化合物、その製造方法および用途 | |
| JP2022545326A (ja) | 複素環化合物、その製造方法及びその使用方法 | |
| WO2021052501A1 (zh) | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 | |
| CA3030697C (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| CA3216045A1 (en) | Compounds as pd1/pd-l1 inhibitors and methods thereof | |
| HK40085726A (en) | Quinazoline compounds, preparation methods and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240614 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240614 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250522 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250820 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260403 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260410 |